Verastem, Inc. – NASDAQ:VSTM
Verastem stock price today
$7.93
+4.22
+113.75%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Verastem stock price monthly change
+10.42%
month
Verastem stock price quarterly change
+10.42%
quarter
Verastem stock price yearly change
-55.30%
year
Verastem key metrics
Market Cap | 180.25M |
Enterprise value | 3.11M |
P/E | -1 |
EV/Sales | 0.59 |
EV/EBITDA | -0.04 |
Price/Sales | 14.54 |
Price/Book | 1.59 |
PEG ratio | -0.05 |
EPS | -4.4 |
Revenue | N/A |
EBITDA | -101.22M |
Income | -105.51M |
Revenue Q/Q | N/A |
Revenue Y/Y | -95.60% |
Profit margin | -1421.65% |
Oper. margin | -1404.8% |
Gross margin | 0% |
EBIT margin | -1404.8% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeVerastem stock price history
Verastem stock forecast
Verastem financial statements
| Jun 2023 | 0 | -24.28M | |
|---|---|---|---|
| Sep 2023 | 0 | -20.00M | |
| Dec 2023 | 114K | -27.36M | -24007.02% |
| Mar 2024 | 0 | -33.86M |
| Dec 2023 | 114K | -27.36M | -24007.02% |
|---|---|---|---|
| Mar 2024 | 0 | -33.86M | |
| Oct 2025 | 1.16M | -25.04M | -2145.33% |
| Dec 2025 | 1.73M | -25.49M | -1468.91% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 191758000 | 69.00M | 35.99% |
|---|---|---|---|
| Sep 2023 | 176153000 | 71.81M | 40.77% |
| Dec 2023 | 149718000 | 71.18M | 47.55% |
| Mar 2024 | 123539000 | 77.31M | 62.59% |
| Jun 2023 | -19.90M | 14M | 91.48M |
|---|---|---|---|
| Sep 2023 | -16.58M | -70.07M | -891K |
| Dec 2023 | -29.68M | 12.43M | -446K |
| Mar 2024 | -28.30M | 30.97M | 846K |
Verastem alternative data
| Aug 2023 | 57 |
|---|---|
| Sep 2023 | 57 |
| Oct 2023 | 57 |
| Nov 2023 | 57 |
| Dec 2023 | 57 |
| Jan 2024 | 57 |
| Feb 2024 | 57 |
| Mar 2024 | 73 |
| Apr 2024 | 73 |
| May 2024 | 73 |
| Jun 2024 | 73 |
| Jul 2024 | 73 |
Verastem other data
66.49%
+0.95%
of VSTM is owned by hedge funds
126
-20
115.96M
-1.91M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 9210 |
| Feb 2024 | 0 | 9204 |
| Mar 2024 | 0 | 1729 |
| Apr 2024 | 0 | 6 |
| Jun 2024 | 0 | 1864 |
| Jul 2024 | 0 | 7 |
| Aug 2024 | 0 | 3245 |
| Sep 2024 | 0 | 1877 |
| Oct 2024 | 0 | 6 |
| Nov 2024 | 0 | 812 |
| Dec 2024 | 0 | 1864 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | CALKINS DANIEL officer: Chief Financial Officer | Common Stock | 28 | $3.91 | $109 | ||
Sale | CALKINS DANIEL officer: Chief Financial Officer | Common Stock | 65 | $4.34 | $282 | ||
Sale | GAGNON ROBERT E. director | Common Stock | 130 | $4.37 | $568 | ||
Sale | GAGNON ROBERT E. director | Common Stock | 130 | $4.37 | $568 | ||
Sale | STUGLIK BRIAN M director | Common Stock | 334 | $4.37 | $1,460 | ||
Sale | PATERSON DAN director, officer: President an.. | Common Stock | 183 | $4.37 | $800 | ||
Sale | GAGNON ROBERT E. director | Common Stock | 285 | $4.54 | $1,294 | ||
Sale | GAGNON ROBERT E. director | Common Stock | 285 | $4.54 | $1,294 | ||
Sale | STUGLIK BRIAN M director | Common Stock | 595 | $4.54 | $2,701 | ||
Sale | PATERSON DAN director, officer: President an.. | Common Stock | 244 | $4.54 | $1,108 |
| Quarter | Transcript |
|---|---|
| Q3 2019 30 Oct 2019 | Q3 2019 Earnings Call Transcript |
| Q2 2019 2 Aug 2019 | Q2 2019 Earnings Call Transcript |
| Q1 2019 10 May 2019 | Q1 2019 Earnings Call Transcript |
| Q4 2018 13 Mar 2019 | Q4 2018 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Brian M. Stuglik BPHARM, R.Ph., RPh (1959) Chief Executive Officer & Director | $1,160,000 |
Mr. Daniel W. Paterson (1961) Chief Operating Officer & Pres | $780,110 |
| Mr. Robert E. Gagnon (1974) Chief Bus. & Financial Officer | $651,220 |
Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers
Tempus AI: I Believe In The Company's Cause
Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination
Verastem: Planning The PDUFA Run-Up
Verastem: BLA Acceptance Puts Key Goals In Sight
Verastem: Market Overreaction Creates A Dip Buying Opportunity
Verastem: A Shocking Drop On 'Positive' Data (Maintain Buy)
Verastem: Other Catalysts In 2024 Beyond NDA Rolling Submission Of Defactinib
Verastem: Potential Accelerated Approval Filing In H1 2024
-
What's the price of Verastem stock today?
One share of Verastem stock can currently be purchased for approximately $7.93.
-
When is Verastem's next earnings date?
Unfortunately, Verastem's (VSTM) next earnings date is currently unknown.
-
Does Verastem pay dividends?
No, Verastem does not pay dividends.
-
How much money does Verastem make?
Verastem has a market capitalization of 180.25M.
-
What is Verastem's stock symbol?
Verastem, Inc. is traded on the NASDAQ under the ticker symbol "VSTM".
-
What is Verastem's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Verastem?
Shares of Verastem can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Verastem's key executives?
Verastem's management team includes the following people:
- Mr. Brian M. Stuglik BPHARM, R.Ph., RPh Chief Executive Officer & Director(age: 66, pay: $1,160,000)
- Mr. Daniel W. Paterson Chief Operating Officer & Pres(age: 64, pay: $780,110)
- Mr. Robert E. Gagnon Chief Bus. & Financial Officer(age: 51, pay: $651,220)
-
How many employees does Verastem have?
As Jul 2024, Verastem employs 73 workers.
-
When Verastem went public?
Verastem, Inc. is publicly traded company for more then 13 years since IPO on 27 Jan 2012.
-
What is Verastem's official website?
The official website for Verastem is verastem.com.
-
Where are Verastem's headquarters?
Verastem is headquartered at 117 Kendrick Street, Needham, MA.
-
How can i contact Verastem?
Verastem's mailing address is 117 Kendrick Street, Needham, MA and company can be reached via phone at +7 812924200.
Verastem company profile:
Verastem, Inc.
verastem.comExchange:
NASDAQ
Full time employees:
73
Industry:
Biotechnology
Sector:
Healthcare
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
117 Kendrick Street
Needham, MA 02494
Needham, MA 02494
CIK: 0001526119
ISIN: US92337C2035
CUSIP: 92337C104
